Adis JournalsBrowse
Summary slide.png (123.22 kB)
Download file

Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)

Download (123.22 kB)
figure
posted on 2020-12-01, 16:55 authored by Ana-Maria Orbai, Jordi Gratacós, Anthony Turkiewicz, Stephen Hall, Eva Dokoupilova, Bernard Combe, Peter Nash, Gaia Gallo, Clinton C. Bertram, Amanda M. Gellett, Aubrey Trevelin Sprabery, Julie Birt, Lisa Macpherson, Vladimir J. Geneus, Arnaud Constantin

Article full text


The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2020.

History

References

Usage metrics

Read the peer-reviewed publication

Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)
Rheumatology and TherapyRheumatology and Therapy

Categories

Keywords

EfficacyInterleukin-17AIxekizumabPsoriatic arthritisSafety

Licence

CC BY-NC 4.0

Exports